New research suggests that viruses and metals in the brain may exacerbate Alzheimer disease and deep brain stimulation shows promise in slowing cognitive decline.
Although these medication-assisted treatments have been approved by the FDA and have strong empiric evidence for superior outcomes, it is important to know the good and the bad.
Highlights of 3 new studies investigate how to choose the best therapy for depression as well as the negative influences of polypharmacy and social media.
The immune-brain loop: a world where more and more clinicians boldly go—and thrive—among new discoveries.
This month's roundup features noteworthy stories from around the web: the humanitarian crisis at the border, new gaming disorder diagnosis, a medication investigation of over 26,000 adult patients, a boundary-busting neurologist, and physician and celebrity suicides.
Revival of an old drug, declaration of independence for seniors, inmates doing more than time—these and other stories are covered in our monthly roundup.
For the first time, a study has shown comprehensive evidence for the effect of depression on decline in overall cognitive function. Plus, 2 more findings.
Negative symptoms identified from the Negative Symptom Assessment and the behaviors that might be observed in each of 5 domains.
Three new studies examine research on biomarkers to predict lifetime risk of Alzheimer disease; diet and brain tissue volume; and cognitive impairment in active older adults.
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.